Safety and Efficacy of SCH 32088 vs Beclomethasone Dipropionate (Vancenase AQ) and Placebo in Seasonal Allergic Rhinitis
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 345
- 主要终点
- Number of Participants Who Discontinued Treatment Due to An Adverse Event (AE)
研究概览
简要总结
The objectives of this study are to determine the safety and efficacy in seasonal allergic rhinitis of a four-week course of mometasone furoate compared to beclomethasone dipropionate or placebo.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 12 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Nonpregnant women of childbearing potential must be using a medically acceptable form of birth control for at least 3 months prior to Screening, and must continue its use for the duration of the study. Women not of childbearing potential must be surgically sterilized or at least one year post menopausal, or be otherwise incapable of bearing children
- •2-year history of seasonal allergic rhinitis
- •Positive skin test response to a local seasonal allergen within last 2 years
- •Good health and free of any unstable, clinically significant disease, other than allergic rhinitis, that would interfere with the study schedule or evaluation of seasonal allergic rhinitis
排除标准
- •Women who are pregnant or breastfeeding
- •Women of childbearing potential who are not using an acceptable form of birth control
- •Pre-menarchal females
- •Asthma requiring therapy with inhaled or systemic corticosteroids
- •Significant renal, hepatic, neurologic, cardiovascular, hematologic, metabolic, cerebrovascular, respiratory, gastrointestinal, or other significant medical illness or disorder which, in the judgment of the investigator, may interfere with the study, or require treatment which might interfere with the study
- •On immunotherapy (unless maintenance therapy)
- •Upper respiratory tract or sinus infection that requires antibiotic therapy within the previous 2 weeks
- •Use of any investigational drug within the previous 90 days unless the investigational drug is a nasal corticosteroid or has a short (12 hours or less) duration of action, in which case the washout period will be 30 days
- •Large nasal polyps, marked septal deviations or any other nasal structural abnormality that significantly interferes with nasal air flow
- •Allergy to corticosteroids, or a history of multiple drug allergies
- •History of posterior subcapsular cataracts
- •Dependence upon nasal, oral or ocular decongestants or who are diagnosed with rhinitis medicamentosa
- •Chronic use of any medication which could affect the course of seasonal allergic rhinitis
- •Clinically significant abnormal electrocardiogram (ECG)
研究组 & 干预措施
Mometasone Furoate (MF)
Participants receive 200 mcg nasal MF in the morning upon awakening and placebo approximately 12 hours later in the evening (200 mcg total daily dose) for 29 days.
干预措施: Mometasone Furoate (MF) (Drug)
Mometasone Furoate (MF)
Participants receive 200 mcg nasal MF in the morning upon awakening and placebo approximately 12 hours later in the evening (200 mcg total daily dose) for 29 days.
干预措施: Placebo (Drug)
Beclomethasone Dipropionate (BDP)
Participants receive 168 mcg nasal BDP in the morning upon awakening and an additional 168 mcg approximately 12 hours later in the evening (336 mcg total daily dose) for 29 days.
干预措施: Beclomethasone Dipropionate (BDP) (Drug)
Placebo
Participants receive nasal placebo in the morning upon awakening and again approximately 12 hours later in the evening for 29 days.
干预措施: Placebo (Drug)
结局指标
主要结局
Number of Participants Who Discontinued Treatment Due to An Adverse Event (AE)
时间窗: Up to 31 Days
An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a pre-existing condition that was temporally associated with the use of the Sponsor's product was also an AE. The number of participants who discontinued due to an AE was reported for each treatment group.
Change From Baseline in the Total Nasal Symptom Score (TNSS) (Average of Morning [AM]/Evening [PM] Score) Averaged Over Days 1 to 15 (Participant-Evaluated)
时间窗: Baseline, and Days 1 through 15 (average of 15 days of treatment)
TNSS evaluated participant nasal symptoms of discharge (rhinorrhea), stuffiness, sneezing, and itching, as rated in their diary in the morning (AM) and evening (PM). The 4 individual symptom scores rated as follows: 0 = none, 1 = mild, 2 = moderate, 3 = severe. TNSS was the sum of the 4 individual symptom scores (range= 0-12, higher score indicating more frequent/severe nasal symptoms). For the 15 day interval, participant individual daily scores were totaled and averaged over interval (AM and PM computed separately then averaged) and used to calculate the overall average change from Baseline. Participant average changes were then used to calculate the mean change for each arm for the interval. Average change from Baseline for Days 1-15 = average post-treatment score (Days 1-15) - Baseline average score (average of the Baseline AM/PM diary scores from 3 consecutive days prior to Baseline visit). Negative changes from baseline indicate a decrease in symptom severity.
Number of Participants Who Experienced ≥1 Adverse Event
时间窗: Up to 31 Days
An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a pre-existing condition that was temporally associated with the use of the Sponsor's product was also an AE. The number of participants with at least one AE was reported for each treatment group.
次要结局
- Change From Baseline in the TNSS At Day 15 (Physician-Evaluated)(Baseline (Day 1), Day 15)
- Change From Baseline in Overall Condition of Seasonal Allergic Rhinitis At Day 29 (Physician-Evaluated)(Baseline (Day 1), Day 29)
- Change From Baseline in the TNSS At Day 8 (Physician-Evaluated)(Baseline (Day 1), Day 8)
- Change From Baseline in the TNSS At Day 29 (Physician-Evaluated)(Baseline (Day 1), Day 29)
- Change From Baseline in Overall Condition of Seasonal Allergic Rhinitis At Day 8 (Physician-Evaluated)(Baseline (Day 1), Day 8)
- Change From Baseline in Overall Condition of Seasonal Allergic Rhinitis At Day 15 (Physician-Evaluated)(Baseline (Day 1), Day 15)
- Change From Baseline in Overall Condition of Seasonal Allergic Rhinitis At Day 22 (Physician-Evaluated)(Baseline (Day 1), Day 22)
- Change From Baseline in Overall Condition of Seasonal Allergic Rhinitis At Day 4 (Physician-Evaluated)(Baseline (Day 1), Day 4)
- Change From Baseline in Overall Condition of Seasonal Allergic Rhinitis At Day 4 (Participant-Evaluated)(Baseline (Day 1), Day 4)
- Change From Baseline in Overall Condition of Seasonal Allergic Rhinitis At Day 8 (Participant-Evaluated)(Baseline (Day 1), Day 8)
- Change From Baseline in the TNSS At Day 4 (Physician-Evaluated)(Baseline (Day 1), Day 4)
- Change From Baseline in the TNSS At Day 22 (Physician-Evaluated)(Baseline (Day 1), Day 22)
- Response To Therapy At Day 15 (Physician-Evaluated)(Day 15)
- Response To Therapy At Day 22 (Physician-Evaluated)(Day 22)
- Change From Baseline in Overall Condition of Seasonal Allergic Rhinitis At Day 15 (Participant-Evaluated)(Baseline (Day 1), Day 15)
- Change From Baseline in Overall Condition of Seasonal Allergic Rhinitis At Day 22 (Participant-Evaluated)(Baseline (Day 1), Day 22)
- Change From Baseline in Overall Condition of Seasonal Allergic Rhinitis At Day 29 (Participant-Evaluated)(Baseline (Day 1), Day 29)
- Response To Therapy At Day 4 (Physician-Evaluated)(Day 4)
- Response To Therapy At Day 15 (Participant-Evaluated)(Day 15)
- Response To Therapy At Day 8 (Physician-Evaluated)(Day 8)
- Response To Therapy At Day 29 (Physician-Evaluated)(Day 29)
- Response To Therapy At Day 4 (Participant-Evaluated)(Day 4)
- Response To Therapy At Day 8 (Participant-Evaluated)(Day 8)
- Response To Therapy At Day 22 (Participant-Evaluated)(Day 22)
- Response To Therapy At Day 29 (Participant-Evaluated)(Day 29)